Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data ...
manilatimes12m
ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington's Disease
Administration of LETI-101 in nonhuman primates was well-tolerated and showed the potential for therapeutically relevant nuclease and guide RNA expression across critical brain regions affected by ...